Clinical Trial Update: Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This document describes a Phase 1 dose-escalation and expansion study of GSK525762 in combination with fulvestrant for hormone receptor-positive, HER2-negative …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• GSK525762

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2022-01-27